John A. Lewicki - 01 Jan 2024 Form 3 Insider Report for Mereo Biopharma Group plc (MREO)

Role: Chief Scientific Officer
Signature: /s/ Christine Fox, by power of attorney
Issuer symbol: MREO
Transactions as of: 01 Jan 2024
Net transactions value: $0
Form type: 3
Filing time: 02 Jan 2024, 16:15:23 UTC
Next filing: 26 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MREO	American Depositary Shares representing Ordinary Shares						14,196	01 Jan 2024	By The Lewicki Family Living Trust dated December 6, 2000	F1
holding	MREO	American Depositary Shares representing Ordinary Shares						4,003	01 Jan 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	MREO	Share Options (Right to buy)							01 Jan 2024	American Depositary Shares	100,000	$2.77	Direct	F1, F2
holding	MREO	Share Options (Right to buy)							01 Jan 2024	American Depositary Shares	100,000	$2.72	Direct	F1, F3
holding	MREO	Share Options (Right to buy)							01 Jan 2024	American Depositary Shares	160,000	$1.40	Direct	F1, F4
holding	MREO	Share Options (Right to buy)							01 Jan 2024	American Depositary Shares	220,000	$1.01	Direct	F1, F5
holding	MREO	Performance Based Restricted Stock Unit							01 Jan 2024	American Depositary Shares	115,000		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2	25% of the shares underlying this share option vested and became exercisable on August 12, 2021, with the remainder vesting in equal monthly installments for the three years thereafter.
F3	25% of the shares underlying this share option vested and became exercisable on February 1, 2022, with the remainder vesting in equal monthly installments for the three years thereafter.
F4	25% of the shares underlying this share option vested and became exercisable on January 14, 2023, with the remainder vesting in equal monthly installments for the three years thereafter.
F5	25% of the shares underlying this share option will vest and become exercisable on January 25, 2024, with the remainder vesting in equal monthly installments for the three years thereafter.
F6	Each performance based restricted stock unit ("PSU") represents the conditional right to receive one ADS and shall vest upon satisfaction of four escalating ADS price threshold values over a two year performance period. The number included in column 3 of Table II reflects the number of PSUs eligible for vesting. If a minimum ADS price threshold is not met, such PSUs may vest at zero ADSs.

Remarks:

Exhibit 24 - Power of Attorney